BR112014027204A2 - conjugados d ácido graxo de estatina e agonistas fxr; composições e método de usos - Google Patents

conjugados d ácido graxo de estatina e agonistas fxr; composições e método de usos

Info

Publication number
BR112014027204A2
BR112014027204A2 BR112014027204A BR112014027204A BR112014027204A2 BR 112014027204 A2 BR112014027204 A2 BR 112014027204A2 BR 112014027204 A BR112014027204 A BR 112014027204A BR 112014027204 A BR112014027204 A BR 112014027204A BR 112014027204 A2 BR112014027204 A2 BR 112014027204A2
Authority
BR
Brazil
Prior art keywords
fatty acid
statin
conjugate
compositions
conjugates
Prior art date
Application number
BR112014027204A
Other languages
English (en)
Inventor
Wensley Allison
Ting Amal
B Vu Chi
C Milne Jill
R Jirousek Michael
Original Assignee
Catabasis Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Catabasis Pharmaceuticals Inc filed Critical Catabasis Pharmaceuticals Inc
Publication of BR112014027204A2 publication Critical patent/BR112014027204A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed

Abstract

abstract the invention relates to fatty acid statin conjugates and fatty acid fxr agonist conjugates; compositions comprising an effective amount of a fatty acid statin conjugate or a fatty acid fxr agonist conjugate; and methods for treating or preventing a metabolic disease comprising the administration of an effective amount of a fatty acid statin conjugate or a fatty acid fxr agonist conjugate. ______________________________________________________________ resumo conjugados d ácido graxo de estatina e agonistas fxr; composições e método de usos a invenção se refere a conjugados de ácido graxo estatina e conjugados de ácido graxo agonista de fxr; composições que compreendem uma quantidade eficaz de um conjugado de ácido graxo estatina ou um conjugado de ácido graxo agonista de fxr; e métodos para tratar ou prevenir uma doença metabólica que compreendem a administração de uma quantidade eficaz de um conjugado ácido graxo estatina ou um conjugado de ácido graxo agonista de fxr.
BR112014027204A 2012-05-01 2013-05-01 conjugados d ácido graxo de estatina e agonistas fxr; composições e método de usos BR112014027204A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261641033P 2012-05-01 2012-05-01
PCT/US2013/039103 WO2013166176A1 (en) 2012-05-01 2013-05-01 Fatty acid conjugates of statin and fxr agonists; compositions and method of uses

Publications (1)

Publication Number Publication Date
BR112014027204A2 true BR112014027204A2 (pt) 2017-06-27

Family

ID=49514864

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014027204A BR112014027204A2 (pt) 2012-05-01 2013-05-01 conjugados d ácido graxo de estatina e agonistas fxr; composições e método de usos

Country Status (9)

Country Link
US (2) US9084826B2 (pt)
EP (1) EP2844257A4 (pt)
KR (1) KR20150004894A (pt)
AU (1) AU2013256362A1 (pt)
BR (1) BR112014027204A2 (pt)
CA (1) CA2871772A1 (pt)
IL (1) IL235432A0 (pt)
MX (1) MX2014013150A (pt)
WO (1) WO2013166176A1 (pt)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG178948A1 (en) 2009-09-01 2012-04-27 Catabasis Pharmaceuticals Inc Fatty acid niacin conjugates and their uses
USRE46608E1 (en) 2009-09-01 2017-11-14 Catabasis Pharmaceuticals, Inc. Fatty acid niacin conjugates and their uses
CN105916378A (zh) * 2013-11-15 2016-08-31 克塔巴西斯制药有限公司 脂肪酸烟酸缀合物
SG11201703717SA (en) 2014-11-06 2017-06-29 Enanta Pharm Inc Bile acid analogs an fxr/tgr5 agonists and methods of use thereof
WO2016086115A1 (en) 2014-11-26 2016-06-02 Enanta Pharmaceuticals, Inc. Tetrazole derivatives of bile acids as fxr/tgr5 agonists and methods of use thereof
MA41031A (fr) 2014-11-26 2017-10-03 Catabasis Pharmaceuticals Inc Conjugués cystéamine-acide gras et leur utilisation comme activateurs de l'autophagie
US10208081B2 (en) 2014-11-26 2019-02-19 Enanta Pharmaceuticals, Inc. Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof
AU2015353473A1 (en) 2014-11-26 2017-06-08 Enanta Pharmaceuticals, Inc. Bile acid analogs as FXR/TGR5 agonists and methods of use thereof
SG11201706089RA (en) * 2015-02-11 2017-09-28 Enanta Pharm Inc Bile acid analogs as fxr/tgr5 agonists and methods of use thereof
MY192135A (en) 2015-03-31 2022-07-29 Enanta Pharm Inc Bile acid derivatives as fxr/tgr5 agonists and methods of use thereof
CN109071593B (zh) * 2016-01-28 2021-01-15 正大天晴药业集团股份有限公司 甾体类衍生物fxr激动剂
WO2017147174A1 (en) 2016-02-23 2017-08-31 Enanta Pharmaceuticals, Inc. Heteroaryl containing bile acid analogs as fxr/tgr5 agonists and methods of use thereof
US10323060B2 (en) 2016-02-23 2019-06-18 Enanta Pharmaceuticals, Inc. Benzoic acid derivatives of bile acid as FXR/TGR5 agonists and methods of use thereof
WO2017147159A1 (en) 2016-02-23 2017-08-31 Enanta Pharmaceuticals, Inc. Deuterated bile acid derivatives as fxr/tgr5 agonists and methods of use thereof
WO2017189651A1 (en) 2016-04-26 2017-11-02 Enanta Pharmaceuticals, Inc. Isoxazole derivatives as fxr agonists and methods of use thereof
WO2017189652A1 (en) 2016-04-26 2017-11-02 Enanta Pharmaceuticals, Inc. Isoxazole derivatives as fxr agonists and methods of use thereof
WO2017189663A1 (en) 2016-04-26 2017-11-02 Enanta Pharmaceuticals, Inc. Isoxazole derivatives as fxr agonists and methods of use thereof
US10144729B2 (en) 2016-05-18 2018-12-04 Enanta Pharmaceuticals, Inc. Isoxazole analogs as FXR agonists and methods of use thereof
WO2017201155A1 (en) 2016-05-18 2017-11-23 Enanta Pharmaceuticals, Inc. lSOXAZOLE DERIVATIVES AS FXR AGONISTS AND METHODS OF USE THEREOF
WO2017201152A1 (en) 2016-05-18 2017-11-23 Enanta Pharmaceuticals, Inc. Isoxazole derivatives as fxr agonists and methods of use thereof
WO2018067704A1 (en) 2016-10-04 2018-04-12 Enanta Pharmaceuticals, Inc. Isoxazole analogs as fxr agonists and methods of use thereof
WO2018081285A1 (en) 2016-10-26 2018-05-03 Enanta Pharmaceuticals, Inc. Urea-containing isoxazole derivatives as fxr agonists and methods of use thereof
ES2918698T3 (es) 2016-11-29 2022-07-19 Enanta Pharm Inc Proceso para la preparación de derivados del ácido biliar de las sulfonilureas
WO2018152171A1 (en) 2017-02-14 2018-08-23 Enanta Pharmaceuticals, Inc. Bile acid derivatives as fxr agonists and methods of use thereof
US10676500B2 (en) 2017-04-07 2020-06-09 Enanta Pharmaceuticals, Inc. Process for preparation of sulfonyl carbamate bile acid derivatives
WO2019118571A1 (en) 2017-12-12 2019-06-20 Enanta Pharmaceuticals, Inc. Isoxazole analogs as fxr agonists and methods of use thereof
US10829486B2 (en) 2018-02-14 2020-11-10 Enanta Pharmacueticals, Inc. Isoxazole derivatives as FXR agonists and methods of use thereof
WO2020231917A1 (en) 2019-05-13 2020-11-19 Enanta Pharmaceuticals, Inc. Isoxazole derivatives as fxr agonists and methods of use thereof

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9508823D0 (en) * 1995-05-01 1995-06-21 Scotia Holdings Plc Drug Derivatives
US6576636B2 (en) * 1996-05-22 2003-06-10 Protarga, Inc. Method of treating a liver disorder with fatty acid-antiviral agent conjugates
IL142650A (en) * 1998-04-08 2007-06-03 Galmed Int Ltd Use of bile acid conjugates or bile salts and fatty acids or fatty acids in the preparation of pharmaceuticals for lowering cholesterol, for the treatment of fatty liver and for the treatment of hyperglycemia and diabetes
AU1482102A (en) * 2000-11-14 2002-05-27 Tocovite Pty Ltd Complexes of phosphate derivatives
US20020077317A1 (en) * 2000-12-15 2002-06-20 Das Undurti Narasimha Method of potentating the action of 2-methoxyoestradiol, statins and C-peptide of proinsulin
TW200616604A (en) * 2004-08-26 2006-06-01 Nicholas Piramal India Ltd Nitric oxide releasing prodrugs containing bio-cleavable linker
WO2006062748A2 (en) * 2004-12-06 2006-06-15 Reliant Pharmaceuticals, Inc. Omega-3 fatty acids and dyslipidemic agent for lipid therapy
MX2007011031A (es) * 2005-03-08 2008-04-21 Reliant Pharmaceuticals Inc Tratamiento con estatina y acidos grasos omega-3 y un producto de combinacion de los mismos.
CA2681639A1 (en) * 2006-03-22 2007-10-04 Syndexa Pharmaceuticals Corporation Compounds and methods for treatment of disorders associated with er stress
CA2687165A1 (en) * 2007-06-25 2008-12-31 Nicox S.A. Use of nitric oxide-releasing statins in the treatment of pulmonary arterial hypertension
FR2937537A1 (fr) * 2008-10-29 2010-04-30 Centre Nat Rech Scient Nanoparticules de statine
SG178948A1 (en) * 2009-09-01 2012-04-27 Catabasis Pharmaceuticals Inc Fatty acid niacin conjugates and their uses
US20110082156A1 (en) * 2009-10-05 2011-04-07 Milne Jill C Fatty acid acipimox derivatives and their uses
WO2011044139A1 (en) * 2009-10-05 2011-04-14 Catabasis Pharmaceuticals, Inc. Fatty acid acifran derivatives and their uses
WO2011044141A1 (en) * 2009-10-05 2011-04-14 Catabasis Pharmaceuticals, Inc. Fatty acid fibrate derivatives and their uses
MX337605B (es) * 2010-01-08 2016-03-10 Catabasis Pharmaceuticals Inc Derivados de fumarato de acido graso y sus usos.
WO2011109681A1 (en) 2010-03-05 2011-09-09 Catabasis Pharmaceuticals, Inc. Fatty acid cox inhibitor derivatives and their uses
WO2011149766A2 (en) * 2010-05-23 2011-12-01 Jingxuan Kang Lipid-tailored pharmaceutical agents
US8609138B2 (en) * 2010-06-30 2013-12-17 Mochida Pharmaceutical Co., Ltd. ω3 fatty acid compound preparation
CN103841961A (zh) * 2011-07-28 2014-06-04 雪松-西奈医学中心 在两亲性间隔基或两亲性聚合物上包含治疗剂的抗氧化剂、神经保护和抗肿瘤纳米颗粒

Also Published As

Publication number Publication date
KR20150004894A (ko) 2015-01-13
EP2844257A4 (en) 2016-06-01
US20160015819A1 (en) 2016-01-21
MX2014013150A (es) 2015-05-11
EP2844257A1 (en) 2015-03-11
IL235432A0 (en) 2014-12-31
CA2871772A1 (en) 2013-11-07
WO2013166176A1 (en) 2013-11-07
US20130316995A1 (en) 2013-11-28
AU2013256362A1 (en) 2014-11-13
US9084826B2 (en) 2015-07-21

Similar Documents

Publication Publication Date Title
BR112014027204A2 (pt) conjugados d ácido graxo de estatina e agonistas fxr; composições e método de usos
BRPI0915536A2 (pt) salicilatos acetilados de ácidos graxos e seus usos
ECSP12012097A (es) Derivados de fumarato de ácido graso y sus usos
BR112017005693A2 (pt) método para tratar e/ou prevenir uma doença hepática, e, composição farmacêutica.
NI201200038A (es) Conjugados de niacina y ácidos grasos y sus usos
BR112014032905A2 (pt) métodos de redução do risco de um evento cardiovascular em um sujeito em terapia com estatina
BR112012006692A2 (pt) composição farmacêutica compreendendo ácido graxo de omega-3 e um derivado de hidróxi de uma estatina e métodos de uso das mesmas
PH12015502136A1 (en) Compositions and methods for treating non-alcoholic steatohepatitis
CL2010001526A1 (es) Compuestos derivados de isonicotinamida, moduladores de la estearoil-coa-desaturasa; composicion farmaceutica que comprende un compuesto;utiles para tratar enfermedades relacionadas con dislipidemia y trastornos del metabolismo de lipidos.
BR112014031394A2 (pt) composições e métodos para absorção transmucosa
BR112014006220A2 (pt) composições de galacto-ramnogalacturonato para o tratamento de esteatohepatite não alcoólica e de doença de gordura no fígado não alcoólica
CL2012002424A1 (es) Método para tratar artitris reumatoide que comprende administrar al paciente laquinimod y metotrexato por vía oral; composición farmacéutica que los comprende.
BR112015022972A2 (pt) composição farmacêutica de cloridrato de s-cetamina
BR112014020113A8 (pt) Composições farmacêuticas e método para diminuir a frequência de micção
BR112016003584A8 (pt) composições farmaceuticas e uso das mesmas para regressão de placa acelerada
MX2022001796A (es) Metodos y composiciones para inhibir los sintomas asociados con la veisalgia.
BR112014030279A2 (pt) métodos para tratamento de neutropenia usando agonistas retinóide
BR112015029897A2 (pt) composição sólida para administração oral contendo ácido ibandrônico ou um seu sal farmaceuticamente aceitável e vitamina d e processo para obtenção da referida composição
PE20150190A1 (es) Formulacion farmaceutica
BR112017008033A2 (pt) composição farmacêutica para administração oral e respectivo processo de preparação
BR112015022513A2 (pt) produto e método para tratamento de diarreia
BR112015001627A2 (pt) composição farmacêutica, respectivos usos e método para diminuir a frequência de micção
BR112013003064A2 (pt) agente profilático ou terapêutico para a esteato-hepatite não alcoólica
BR112015022117A2 (pt) precursor da composição cosmética, composição cosmética para a aplicação tópica, método para a administração de um agente cosmético sólido e amida de triciclodecano
UY34080A (es) Composición farmacéutica para administración oral que comprende fexofenadina y métodos de preparación

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]